Loading company…
Mapi Pharma Ltd. develops long-acting injectable medicines for multiple sclerosis and neuropathic pain, based in Israel.
Founded in 2008 and headquartered in Israel, Mapi Pharma Ltd. develops and manufactures long-acting depot injectable pharmaceuticals, mainly for multiple sclerosis and neuropathic pain. Its lead product is Glatiramer Acetate Depot, a once-monthly injection, and it is also advancing long-acting Pregabalin, Paliperidone Palmitate and Buspirone ER. The company raised USD 10 mn in a financing round led by aMoon Partners on August 17, 2017, and is at Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in